Condition: Pre Diabetes · Postpartum Disorder · Sponsor: Woman's
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.
This description comes directly from the study's public registry record.
Briasha Jones, MPH · 225-924-8446 · briasha.jones@womans.org
Elizabeth Sutton, PhD · 225-924-8446 · elizabeth.sutton@womans.org
Always discuss trial participation with your own doctor first.
| Woman's Hospital | Baton Rouge, Louisiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04873050